Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03090620 · ClinicalTrials.gov registry record · Phase 4
Treatment of Adolescent Antimuscarinic (Anticholinergic) Toxidrome
A Phase 4 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 4
- Development phase
- 19
- Enrollment target
NCT03090620 is a Phase 4 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 19 participants.
The verdict
NCT03090620, a Phase 4 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 19 participants
- Enrollment target
Study Summary
Overdose of xenobiotics (antihistamines, antipsychotics, or Jimson Weed) with resulting antimuscarinic toxidrome is a common scenario in medical toxicology. The result of antagonism of muscarinic receptors is a constellation of signs and symptoms (toxidrome): mydriasis, decreased sweat, decreased bowel sounds, agitation, delirium, hallucinations, urinary retention, tachycardia, flushed skin and seizures. Two treatment options are physostigmine or benzodiazepines. Although the antimuscarinic toxidrome occurs commonly, physostigmine has been used sparingly despite evidence of safety and efficacy. To demonstrate the utility and safety of physostigmine, the investigators propose a randomized clinical trial of physostigmine compared to benzodiazepine for antimuscarinic toxicity.
Interventions
- DRUG Lorazepam
- DRUG Physostigmine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2017-03-30 |
| Est. Completion | 2020-08-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03090620
The ClinicalTrials.gov registry entry for NCT03090620 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lorazepam is the first listed.
NCT03090620 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03090620 about?
NCT03090620 is a clinical study titled "Treatment of Adolescent Antimuscarinic (Anticholinergic) Toxidrome". Overdose of xenobiotics (antihistamines, antipsychotics, or Jimson Weed) with resulting antimuscarinic toxidrome is a common scenario in medical toxicology. The result of antagonism of muscarinic receptors is a constellation of signs and symptoms (toxidrome): mydriasis, decreased sweat, decreased bo...
What is the current status of trial NCT03090620?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 19 participants. The study started on 2017-03-30. Estimated completion is 2020-08-31.
What interventions are being tested in trial NCT03090620?
The interventions under investigation include: Lorazepam (DRUG), Physostigmine (DRUG).
Who is sponsoring clinical trial NCT03090620?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.